These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 34756214)

  • 1. A dynamic prediction engine to prevent chemotherapy-induced nausea and vomiting.
    Mosa ASM; Hossain AM; Yoo I
    Artif Intell Med; 2020 Sep; 109():101925. PubMed ID: 34756214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Smartphone-Based Decision Support Tool for Predicting Patients at Risk of Chemotherapy-Induced Nausea and Vomiting: Retrospective Study on App Development Using Decision Tree Induction.
    Mosa ASM; Rana MKZ; Islam H; Hossain AKMM; Yoo I
    JMIR Mhealth Uhealth; 2021 Dec; 9(12):e27024. PubMed ID: 34860677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.
    Natale JJ
    Hosp Pract (1995); 2015; 43(4):226-34. PubMed ID: 26308912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study.
    Molassiotis A; Aapro M; Dicato M; Gascon P; Novoa SA; Isambert N; Burke TA; Gu A; Roila F
    J Pain Symptom Manage; 2014 May; 47(5):839-848.e4. PubMed ID: 24075401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan.
    Tamura K; Aiba K; Saeki T; Nakanishi Y; Kamura T; Baba H; Yoshida K; Yamamoto N; Kitagawa Y; Maehara Y; Shimokawa M; Hirata K; Kitajima M;
    Int J Clin Oncol; 2015 Oct; 20(5):855-65. PubMed ID: 25681876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study.
    Hilarius DL; Kloeg PH; van der Wall E; van den Heuvel JJ; Gundy CM; Aaronson NK
    Support Care Cancer; 2012 Jan; 20(1):107-17. PubMed ID: 21258948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Adherence to Antiemetic Treatment Guidelines in Patients With Chemotherapy-Induced Nausea and Vomiting in Teaching Hospitals in Tehran.
    Nikbakht Z; Rajabi M; Shahrasbi A; Roohi E; Hashemian F
    J Cancer Educ; 2021 Oct; 36(5):1022-1029. PubMed ID: 31955393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Personalized Estimate of Chemotherapy-Induced Nausea and Vomiting: Development and External Validation of a Nomogram in Cancer Patients Receiving Highly/Moderately Emetogenic Chemotherapy.
    Hu Z; Liang W; Yang Y; Keefe D; Ma Y; Zhao Y; Xue C; Huang Y; Zhao H; Chen L; Chan A; Zhang L
    Medicine (Baltimore); 2016 Jan; 95(2):e2476. PubMed ID: 26765450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers.
    Ihbe-Heffinger A; Ehlken B; Bernard R; Berger K; Peschel C; Eichler HG; Deuson R; Thödtmann J; Lordick F
    Ann Oncol; 2004 Mar; 15(3):526-36. PubMed ID: 14998860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of chemotherapy-induced nausea and vomiting among cancer patients receiving moderately to highly emetogenic chemotherapy in cancer centers in Sichuan, China.
    Sun Y; Zheng Y; Yang X; Xie K; Du C; He L; Gui Y; Fu J; Li C; Zhang H; Zhu L; Bie J; Sun Y; Fu Y; Zhou Y; Shou F; Wang Y; Zhu J
    J Cancer Res Clin Oncol; 2021 Sep; 147(9):2701-2708. PubMed ID: 33586045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncologist perspectives on chemotherapy-induced nausea and vomiting (CINV) management and outcomes: A quantitative market research-based survey.
    Aapro M; Ruffo P; Panteri R; Costa S; Piovesana V
    Cancer Rep (Hoboken); 2018 Dec; 1(4):e1127. PubMed ID: 32729252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy-induced nausea and vomiting: incidence and characteristics of persistent symptoms and future directions NCCTG N08C3 (Alliance).
    Kottschade L; Novotny P; Lyss A; Mazurczak M; Loprinzi C; Barton D
    Support Care Cancer; 2016 Jun; 24(6):2661-7. PubMed ID: 26768436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy-induced nausea and vomiting is less controlled at delayed phase in patients with esophageal cancer: a prospective registration study by the CINV Study Group of Japan.
    Baba Y; Baba H; Yamamoto S; Shimada H; Shibata T; Miyazaki T; Yoshikawa T; Nakajima Y; Tsuji Y; Shimokawa M; Kitagawa Y; Aiba K
    Dis Esophagus; 2017 Feb; 30(2):1-7. PubMed ID: 27001532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of clinical outcomes and efficacy of palonosetron and granisetron in combination with dexamethasone in Egyptian patients receiving highly emetogenic chemotherapy.
    A Mahrous M; A El-Azab G; A Tawfik H
    Cancer Chemother Pharmacol; 2021 Jul; 88(1):121-129. PubMed ID: 33835230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study.
    Matsui R; Suzuki K; Takiguchi T; Nishio M; Koike T; Hayashi T; Seto T; Kogure Y; Nogami N; Fujiwara K; Kaneda H; Harada T; Shimizu S; Kimura M; Kenmotsu H; Shimokawa M; Goto K
    BMC Pharmacol Toxicol; 2020 Oct; 21(1):72. PubMed ID: 33023657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of breakthrough and prevention of refractory chemotherapy-induced nausea and vomiting in pediatric cancer patients: Clinical practice guideline update.
    Patel P; Robinson PD; Phillips R; Baggott C; Devine K; Gibson P; Guilcher GMT; Holdsworth MT; Neumann E; Orsey AD; Spinelli D; Thackray J; van de Wetering M; Cabral S; Sung L; Dupuis LL
    Pediatr Blood Cancer; 2023 Aug; 70(8):e30395. PubMed ID: 37178438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adherence to antiemetic guidelines in patients with malignant glioma: a quality improvement project to translate evidence into practice.
    Affronti ML; Schneider SM; Herndon JE; Schlundt S; Friedman HS
    Support Care Cancer; 2014 Jul; 22(7):1897-905. PubMed ID: 24570103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
    Navari RM
    J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overview of the prevention and management of CINV.
    Natale JJ
    Am J Manag Care; 2018 Oct; 24(18 Suppl):S391-S397. PubMed ID: 30328690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Palonosetron versus other 5-HT(3) receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with cancer on chemotherapy in a hospital outpatient setting.
    Balu S; Buchner D; Craver C; Gayle J
    Clin Ther; 2011 Apr; 33(4):443-55. PubMed ID: 21635990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.